(Q55072067)

17 June 2018

title

Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer. (English)

1 reference

17 June 2018

author

Mark R. Lackner

7

1 reference

17 June 2018

Andrew H. Sims

8

1 reference

17 June 2018

author name string

L M Arthur

1

1 reference

17 June 2018

A K Turnbull

2

1 reference

17 June 2018

L Renshaw

3

1 reference

17 June 2018

J Keys

4

1 reference

17 June 2018

J S Thomas

5

1 reference

17 June 2018

T R Wilson

6

1 reference

17 June 2018

J M Dixon

9

1 reference

17 June 2018

language of work or name

English

0 references

publication date

9 August 2014

1 reference

17 June 2018

Breast Cancer Research and Treatment

published in

1 reference

17 June 2018

volume

147

1 reference

17 June 2018

issue

1

1 reference

17 June 2018

page(s)

211-219

1 reference

17 June 2018

https://scigraph.springernature.com/pub.10.1007/s10549-014-3080-x

exact match

0 references

cites work

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3080-X

Comprehensive molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3080-X

Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3080-X

PIK3CA mutation associates with improved outcome in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3080-X

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3080-X

Mutation of the PIK3CA oncogene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3080-X

The PIK3CA gene is mutated with high frequency in human breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3080-X

Frequent mutation of the PIK3CA gene in ovarian and breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3080-X

Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3080-X

Biomarkers and patient selection for PI3K/Akt/mTOR targeted therapies: current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3080-X

Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3080-X

Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3080-X

Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3080-X

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3080-X

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3080-X

PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3080-X

PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3080-X

Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3080-X

PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3080-X

AKT activation predicts outcome in breast cancer patients treated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3080-X

Modulation of estrogen receptor alpha activity and expression during breast cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3080-X

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3080-X

Activating ESR1 mutations in hormone-resistant metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3080-X

Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3080-X

Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3080-X

Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3080-X

PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3080-X

PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3080-X

Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3080-X

PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3080-X

The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3080-X

Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3080-X

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3080-X

PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3080-X

10.1007/S10549-014-3080-X

21 January 2018

Identifiers

DOI

1 reference

17 June 2018

Dimensions Publication ID

1008664542

0 references

Fatcat ID

release_jpdqo4ibi5fkvhekulrl6kli2a

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/jpdqo4ibi5fkvhekulrl6kli2a

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

25104442

1 reference

17 June 2018